KR101282396B1 - Ｐｓｃａ 단백질에 결합하는 암 진단용 항체 - Google Patents

Ｐｓｃａ 단백질에 결합하는 암 진단용 항체 Download PDF

Info

Publication number
KR101282396B1
KR101282396B1 KR1020117010832A KR20117010832A KR101282396B1 KR 101282396 B1 KR101282396 B1 KR 101282396B1 KR 1020117010832 A KR1020117010832 A KR 1020117010832A KR 20117010832 A KR20117010832 A KR 20117010832A KR 101282396 B1 KR101282396 B1 KR 101282396B1
Authority
KR
South Korea
Prior art keywords
psca
antibody
protein
cancer
cells
Prior art date
Application number
KR1020117010832A
Other languages
English (en)
Korean (ko)
Other versions
KR20110056564A (ko
Inventor
진 구다스
아야 쟈코보비츠
시아오-치 지아
로버트 켄달 모리슨
카렌 제인 메이릭 모리슨
후이 샤오
피아 엠. 챨리타-에이드
아서 비. 라이타노
Original Assignee
어젠시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/857,484 external-priority patent/US7622564B2/en
Application filed by 어젠시스 인코포레이티드 filed Critical 어젠시스 인코포레이티드
Priority claimed from PCT/US2005/017412 external-priority patent/WO2005118864A2/en
Publication of KR20110056564A publication Critical patent/KR20110056564A/ko
Application granted granted Critical
Publication of KR101282396B1 publication Critical patent/KR101282396B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
KR1020117010832A 2004-05-28 2005-05-17 Ｐｓｃａ 단백질에 결합하는 암 진단용 항체 KR101282396B1 (ko)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US10/857,484 2004-05-28
US10/857,484 US7622564B2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (PSCA) variants and subsequences thereof
EPPCT/US2004/017231 2004-05-28
WOPCT/US2004/017231 2004-05-28
PCT/US2004/017231 WO2005014780A2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (psca) variants and subsequences thereof
US61638104P 2004-10-05 2004-10-05
US60/616,381 2004-10-05
US61788104P 2004-10-12 2004-10-12
US60/617,881 2004-10-12
US62131004P 2004-10-21 2004-10-21
US60/621,310 2004-10-21
US63307704P 2004-12-02 2004-12-02
US60/633,077 2004-12-02
US67200005P 2005-04-14 2005-04-14
US60/672,000 2005-04-14
PCT/US2005/017412 WO2005118864A2 (en) 2004-05-28 2005-05-17 Antibodies and related molecules that bind to psca proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067027763A Division KR101215611B1 (ko) 2004-05-28 2006-12-28 Ｐｓｃａ 단백질에 결합하는 항체 및 관련 분자

Publications (2)

Publication Number Publication Date
KR20110056564A KR20110056564A (ko) 2011-05-30
KR101282396B1 true KR101282396B1 (ko) 2013-07-04

Family

ID=44210117

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117010832A KR101282396B1 (ko) 2004-05-28 2005-05-17 Ｐｓｃａ 단백질에 결합하는 암 진단용 항체
KR1020067027763A KR101215611B1 (ko) 2004-05-28 2006-12-28 Ｐｓｃａ 단백질에 결합하는 항체 및 관련 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067027763A KR101215611B1 (ko) 2004-05-28 2006-12-28 Ｐｓｃａ 단백질에 결합하는 항체 및 관련 분자

Country Status (6)

Country Link
KR (2) KR101282396B1 (da)
CN (1) CN102344493B (da)
BR (3) BRPI0511624B1 (da)
IL (1) IL214210A (da)
NO (1) NO341404B1 (da)
SI (1) SI1753871T1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2140269T3 (da) 2007-03-27 2013-12-16 Immunovia Ab Proteinsignatur/markører til at detektere adenocarcinom
KR102355959B1 (ko) * 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
CN104853782A (zh) 2012-12-13 2015-08-19 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US11278619B2 (en) 2014-12-01 2022-03-22 The Trustees Of The University Of Pennsylvania DNA antibody constructs and method of using same
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
ES2221982T3 (es) * 1997-03-10 2005-01-16 The Regents Of The University Of California Antigeno de celulas madre de la prostata (psca).
CN1413220A (zh) * 1999-10-29 2003-04-23 杰南技术公司 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them

Also Published As

Publication number Publication date
IL214210A (en) 2013-01-31
NO341404B1 (no) 2017-10-30
KR20110056564A (ko) 2011-05-30
BR122018073034B8 (da) 2022-10-11
BRPI0520902B1 (pt) 2021-11-30
NO20110647L (no) 2006-12-19
CN102344493B (zh) 2014-09-03
BRPI0520902A2 (pt) 2011-10-25
BRPI0511624B1 (pt) 2022-02-08
KR101215611B1 (ko) 2012-12-28
KR20070047251A (ko) 2007-05-04
BRPI0511624A (pt) 2008-01-02
CN102344493A (zh) 2012-02-08
BR122018073034B1 (pt) 2021-10-13
IL214210A0 (en) 2011-08-31
SI1753871T1 (sl) 2016-01-29

Similar Documents

Publication Publication Date Title
US8013128B2 (en) Antibodies and related molecules that bind to PSCA proteins
US8278424B2 (en) Antibodies that bind to PSCA proteins for diagnosis of cancer
US8206932B2 (en) Antibodies and related molecules that bind to PSCA proteins
KR101215179B1 (ko) Ｓｔｅａｐ-１ 단백질과 결합하는 항체 및 그로부터 유래된분자
JP4651663B2 (ja) Ｐｓｃａタンパク質に結合する抗体および関連分子
JP5480921B2 (ja) １６１ｐ２ｆ１０ｂタンパク質に結合する抗体および関連分子
KR101282396B1 (ko) Ｐｓｃａ 단백질에 결합하는 암 진단용 항체
AU2006237616B2 (en) Antibodies and related molecules that bind to PSCA proteins
US20050136435A1 (en) Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
CA2742088A1 (en) Antibodies that bind psca proteins for diagnosis of cancer
DK1753871T3 (da) Antistoffer og beslægtede molekyler, der binder til psca-proteiner
NO345322B1 (no) Antistoffer og beslektede molekyler som bindes til PSCA Proteiner

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170615

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180615

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20190614

Year of fee payment: 7